Risk prediction in children and adults less than 45 years old with papillary thyroid cancer

References

• American Cancer Society: cancer facts & figures. Atlanta: American Cancer Society; 2015. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf
   Google Scholar
• Aschebrook-Kilfoy B, El K, Bc C, et al. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Ann Surg Oncol. 2013;20:2746–2753.
   PubMed Web of Science ®Google Scholar
• Davies L, Hg W. Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama. 2006;295:2164–2167.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, Surveillance, E., and End Results (SEER). SEER stat fact sheets: thyroid cancer. http://seer.cancer.gov/statfacts/html/thyro.html. American Cancer Society. Thyroid Cancer. 2016. [cited 2016 Jun 16]. Available from: www.cancer.org/thyroid-cancer-pdf.
   Google Scholar
• Lim H,DS, Ja S, Check D, et al. Trends in Thyroid cancer incidence and mortality in the United States. Jama. 2017;317(13): 1338–1348. 4.
   PubMed Web of Science ®Google Scholar
• Rong-Liang Shi NQ, Liao T, Wei W-J, et al. The trend of age-group effect on prognosis in differentiated thyroid cancer. Scientific Reports. 2015;6:27086.
   Web of Science ®Google Scholar
• Edge SB, Edge SB,Compton CC, et al. eds. AJCC cancer staging manual. 7th ed. New York (NY): Springer. 2010
   Google Scholar
• Crile G, Jr HJ. Relationship of the age of the patient to the natural history and prognosis of carcinoma of the thyroid. Ann Surg. 1953;138:33–38.
   PubMed Web of Science ®Google Scholar
• Cady B. An expanded view of riskgroup definition in differentiated thyroid carcinoma. Surgery. 1988;104:947–953.
   PubMed Web of Science ®Google Scholar
• Franssila KO. Prognosis in thyroid carcinoma. Cancer. 1975;36:1138–1146.
   PubMed Web of Science ®Google Scholar
• Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033–1041.
   PubMed Web of Science ®Google Scholar
• Si S, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer. 1998;83:1012–1102.
   PubMed Web of Science ®Google Scholar
• Hay ID, Grant GS, Wf T, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088–1095.
   PubMed Web of Science ®Google Scholar
• Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Contr. 2000;7:229–239.
   PubMedGoogle Scholar
• Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1057, discussion 1057-1058.
   PubMed Web of Science ®Google Scholar
• Lang BH, Chow SM, Cy L, et al. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg. 2007;246:114–121.
   PubMed Web of Science ®Google Scholar
• Voutilainen PE, Siironen P, Franssila KO, et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res. 2003;23:4283–4288.
   PubMed Web of Science ®Google Scholar
• Ito Y, Ichihara K, Masuoka H, et al. Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg. 2010;34(11):2570–2580.
   PubMed Web of Science ®Google Scholar
• Nixon IJ, Kuk D, Wreesmann V, et al. Defining a valid age cutoff in staging of well-differentiated thyroid cancer. Ann Surg Oncol. 2016;23:410–415.
   PubMed Web of Science ®Google Scholar
• Ganly I, Nixon IJ, Wang LY, et al. Survival from differentiated thyroid cancer: what has age got to do with it? Thyroid. 2015;25:1106–1114.
   PubMed Web of Science ®Google Scholar
• Adam MA, Terry Hyslop ST, Scheri RP, et al. Exploring the relationship between patient age and cancer- specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol. 2016;34:4415–4420.
   PubMed Web of Science ®Google Scholar
• Lazar, L, Lebenthal Y, Steinmetz A, et al. Differentiated thyroid carcinoma in pediatric patients: comparison of presentation and course between pre-pubertal children and adolescents. J Pediatr. 2009;154(5):708–714.
   PubMed Web of Science ®Google Scholar
• Sugino, K, Nagahama M, Kitagawa W, et al. Papillary thyroid carcinoma in children and adolescents: long-term follow-up and clinical characteristics. World J Surg. 2015;39(9):2259–2265.
   PubMed Web of Science ®Google Scholar
• Tracy EASS. Reoperative thyroid surgery and parathyroid surgery. In: Teich S, Caniano D, editors. Reoperative pediatric surgery. Totowa, NJ: Humana Press; 2008. p. 103–118.
   Google Scholar
• Tracy ET, Roman SA. Current management of pediatric thyroid disease and differentiated thyroid cancer. Curr Opin Oncol. 2016;28(1):37–42.
   PubMed Web of Science ®Google Scholar
• Jin, X, Masterson, L, Patel, A, et al. Conservative or radical surgery for pediatric papillary thyroid carcinoma: a systematic review of the literature. Int J Pediatr Otorhinolaryngol. 2015;79(10):1620–1624.
   PubMed Web of Science ®Google Scholar
• Nice, T, Pasara, S, Goldfarb, M, et al. Pediatric papillary thyroid cancer >1 cm: is total thyroidectomy necessary? J Pediatr Surg. 2015;50(6):1009–1013.
   PubMed Web of Science ®Google Scholar
• Haugen BRM, Alexander EK, Kc B, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Francis, GL, Waguespack, SG, Bauer, AJ, et al. Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015;25(7):716–759.
   PubMed Web of Science ®Google Scholar
• Powers, PA, Dinauer CA, Tuttle RM, et al. The MACIS score predicts the clinical course of papillary thyroid carcinoma in children and adolescents. J Pedi Endocrinol Metabolism: JPEM. 2004;17(3):339–343.
   PubMed Web of Science ®Google Scholar
• Wada, N, Sugino, K, Mimura, T, et al. Treatment strategy of papillary thyroid carcinoma in children and adolescents: clinical significance of the initial nodal manifestation. Ann Surg Oncol. 2009;16(12):3442–3449.
   PubMed Web of Science ®Google Scholar
• Waguespack SG, Francis G. Initial management and follow-up of differentiated thyroid cancer in children. J Natl Compr Cancer Network: JNCCN. 2010;8(11):1289–1300.
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Enomoto K, Uchino S, et al. Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure. World J Surg. 2012;36(6):1241–1246.
   PubMed Web of Science ®Google Scholar
• Kloos RT. Protecting thyroid cancer patients from untoward effects of radioactive iodine treatment. Thyroid. 2009;19(9):925–928.
   PubMed Web of Science ®Google Scholar
• Sawka, AM, Lea, J, Alshehri, B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol. 2008;68(4):610–617.
   PubMed Web of Science ®Google Scholar
• Schlumberger, M, Eltchaninoff, H, Iung, B, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–1673.
   PubMed Web of Science ®Google Scholar
• Woolner LB, Beahrs OH, Bm B, et al. Classification and prognosis of thyroid carcinoma: a study of 885 cases observed in a thirty year period. Am J Surg. 1961;102:354–387.
   PubMed Web of Science ®Google Scholar
• McConahey WM, Hay ID, Lb W, et al. Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy and outcome. Mayo Clin Proc. 1986;61:978–986.
   PubMed Web of Science ®Google Scholar
• Ito Y, Hirokawa M, Jikuzono T, et al. Extranodal tumor extension to adjacent organs predicts a worse cause-specific survival in patients with papillary thyroid carcinoma. World J Surg. 2007;31(6):1194–1201.
   PubMed Web of Science ®Google Scholar
• Ito Y, Tomoda C, Urono T, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg. 2006;30:780–786.
   PubMed Web of Science ®Google Scholar
• Id H. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990;19:545–576.
   PubMed Web of Science ®Google Scholar
• Id H. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic’s experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc. 2002;113:241–260.
   PubMedGoogle Scholar
• Youngwirth L, Adam MA, Scheri R, et al. Extrathyroidal extension is associated with compromised survival in patients with thyroid cancer. Thyroid. 2017;27(5):626–631.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kudo T, Kihara M, et al. Improvement of lymph node recurrence rate, but not distant recurrence and carcinoma death rates, in patients with papillary thyroid carcinoma after disease-free survival for 5 years. Endocr J. 2012;59(10):895–901.
   PubMed Web of Science ®Google Scholar
• Zw B, LiVolsi V, Sl A, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the national cancer institute thyroid fine-needle aspiration state of the science conference. Diagn Cytopathol. 2008;36(6):425–437.
   PubMed Web of Science ®Google Scholar
• Orloff HSHLA. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. The Laryngoscope. 2011;121:487–491.
   PubMed Web of Science ®Google Scholar
• Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237:399.
   PubMed Web of Science ®Google Scholar
• Gardner RE, Tuttle RM, Burman KD, et al. Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126(3):309–312.
   PubMedGoogle Scholar
• Lundgren CI, Hall P, Dickman PW, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case control study. Cancer. 2006;106:524–531.
   PubMed Web of Science ®Google Scholar
• Lee J, Song Y, Soh EY. Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma. J Korean Med Sci. 2014;29:48–52.
   PubMed Web of Science ®Google Scholar
• Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370–2375.
   PubMed Web of Science ®Google Scholar
• Wu MH, Shen WT, Gosnell J, et al. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. Head Neck. 2015;37(9):1336–1343.
   PubMed Web of Science ®Google Scholar
• Gow, KW, Lensing, S, Hill, DA, et al. Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: an institutional experience and review of the literature. J Pediatr Surg. 2003;38(11):1574–1580.
   PubMed Web of Science ®Google Scholar
• Grigsby, PW, Gal-Or, A, Michalski, JM, et al. Childhood and adolescent thyroid carcinoma. Cancer. 2002;95(4):724–729.
   PubMed Web of Science ®Google Scholar
• Rivkees, SA, Mazzaferri, EL, Verburg, FA, et al. The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy. Endocr Rev. 2011;32(6):798–826.
   PubMed Web of Science ®Google Scholar
• Kim, J, Sun, Z, Adam, MA, et al. Predictors of nodal metastasis in pediatric differentiated thyroid cancer. J Pediatr Surg. 2017;52(1):120–123.
   PubMed Web of Science ®Google Scholar
• Frankenthaler, RA, Sellin, RV, Cangir, A, et al. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg. 1990;160(4):341–343.
   PubMed Web of Science ®Google Scholar
• Golpanian, S, Perez, EA, Tashiro, J, et al. Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients. Pediatr Surg Int. 2016;32(3):201–208.
   PubMed Web of Science ®Google Scholar
• Wang, C, Chen, X, Wei, X, et al. Recurrence factors and prevention of complications of pediatric differentiated thyroid cancer. Asian J Surg. 2017;40(1):55–60.
   PubMed Web of Science ®Google Scholar
• Machens, A, Hinze, R, Thomusch, O, et al. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg. 2002;26(1):22–28.
   PubMed Web of Science ®Google Scholar
• Cooper, DS, Doherty, GM, Haugen, BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
   PubMed Web of Science ®Google Scholar
• Deutschmann, MW, Chin-Lenn, L, Au, J, et al. Extent of central neck dissection among thyroid cancer surgeons: cross-sectional analysis. Head Neck. 2016;38(1):E328–32.
   PubMed Web of Science ®Google Scholar
• Carty, SE, Cooper, DS, Doherty, GM, et al. American Thyroid Association Surgery Working, G. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–1158.
   PubMed Web of Science ®Google Scholar
• Falvo L, Catania A, D’Andrea V, et al. Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma. Ann Surg. 2005;241:640–646.
   PubMed Web of Science ®Google Scholar
• Nishida T, Katayama SI, Tsujimoto M. The clinicopathological significance of histologic vascular invasion in differentiated thyroid carcinoma. Am J Surg. 2002;183:80–86.
   PubMed Web of Science ®Google Scholar
• Akslen LA, Myking AO, Salvesen H, et al. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur J Cancer. 1992;29A:44–51.
   PubMed Web of Science ®Google Scholar
• Pontius LN, Youngwirth LM, Sm T, et al. Lymphovascular invasion is associated with survival for papillary thyroid cancer. Endc Relat Cance. 2016;23(7):555–562.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, O.N.P.c.N.Y., Biddinger PW, et al. (eds). Diagnostic pathology and molecular genetics of the thyroid.1st ed. Philadelphia (PA): Lippincott; 2012. 183–262.
   Google Scholar
• Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007;17:655–661.
   PubMed Web of Science ®Google Scholar
• Morris LG, Shaha AR, Rm T, et al. Tall-cell variant of papillary thyroid carcinoma: a matched-pair analysis of survival. Thyroid. 2010;20:153–158.
   PubMed Web of Science ®Google Scholar
• Hl E, Columnar-cell carcinoma of the thyroid. A report of two cases of an aggressive variant of thyroid carcinoma. Am J Clin Pathol. 1986. 85:77–80.
   PubMed Web of Science ®Google Scholar
• Wenig BM, Thompson LD, Cf A, et al. Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. Cancer. 1998;82:740–753.
   PubMed Web of Science ®Google Scholar
• Asioli S, Erickson LA, Sebo TJ, et al. Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol. 2010;34:44–52. 472.
   PubMed Web of Science ®Google Scholar
• Motosugi U, Murata SI, Nagata K, et al. Thyroid papillary carcinoma with micropapillary and hobnail growth pattern: a histological variant with intermediate malignancy? Thyroid. 2009;19:535–537.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyauchi A, Ishikawa H, et al. Our experience of treatment of cribriform morular variant of papillary thyroid carcinoma; difference in clinicopathological features of FAP-associated and sporadic patients. Endocr J. 2011;58(8):685–689.
   PubMed Web of Science ®Google Scholar
• Tomoda C, Miyauchi A, Uruno T, et al. Cribriform-morular variant of papillary thyroid carcinoma: clue to early detection of familial adenomatous polyposis-associated colon cancer. World J Surg. 2004;28(9):886–889.
   PubMed Web of Science ®Google Scholar
• Levy RA, Hui VW, Sood R, et al. Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP. Fam Cancer. 2014;13(4):547–551.
   PubMed Web of Science ®Google Scholar
• Pradhan D, Sharma A, Mohanty SK. Cribriform-morular variant of papillary thyroid carcinoma. Pathol Res Pract. 2015;211(10):712–716.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Li X, Acharya CR, et al. A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. Oncotarget. 2017. DOI:10.18632/oncotarget.15128
   Web of Science ®Google Scholar
• Namba H, Nakashima M, Hayashi T, et al. Clinical Implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metabolism. 2003;88:4393–4397.
   PubMed Web of Science ®Google Scholar
• Kim KH, Kang DW, Sh K, et al. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45:818–821.
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metabolism. 2003;88:5399–5404.
   PubMed Web of Science ®Google Scholar
• Cohen Y, Rosenbaum E, Clark DP, Zeiger MA, Umbricht CB, Tufano RP, Sidransky D & Westra WH. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res. 2004;10:2761–2765.
   PubMed Web of Science ®Google Scholar
• Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003;63:4561–4567.
   PubMed Web of Science ®Google Scholar
• Vanden Borre P, Schrock A, Pm A, et al. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist. 2017;22(3):255–263.
   PubMed Web of Science ®Google Scholar
• Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxford). 2004;61:239–243.
   PubMed Web of Science ®Google Scholar
• Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metabolism. 2004;89:2414–2420.
   PubMed Web of Science ®Google Scholar
• Mingzhao Xing, ASA, Alzahrani, AS, Carson, KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2014;33:42–50.
   PubMed Web of Science ®Google Scholar
• Lee SE, Hwang TS, Choi YL, et al. Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAFV600E mutation. Thyroid. 2017;27(6):802–810.
   PubMed Web of Science ®Google Scholar
• Dongbin Ahn SP, Park S, Sohn JH, et al. BRAF(V600E) mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris, Nasus, Larynx. 2011;39(2):198–203.
   PubMed Web of Science ®Google Scholar
• Liu T, Wang N, Cao J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2013;33:4978–4984.
   PubMed Web of Science ®Google Scholar
• Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Oncology. 2014;32:2718–2726.
   Web of Science ®Google Scholar
• Melo M, Da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65.
   PubMed Web of Science ®Google Scholar
• Ballester LY, Sarabia SF, Sayeed H, et al. Integrating molecular testing in the diagnosis and management of children with thyroid lesions. Pediatr Dev Pathol. 2016;19(2):94–100.
   PubMed Web of Science ®Google Scholar
• Haugen BR. American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2015 [2017 1];123(3):372–381.
   Web of Science ®Google Scholar
• Pawelczak, M, Cayo, MA, Chen, H Outcomes of children and adolescents with well-differentiated thyroid carcinoma and pulmonary metastases following 131I treatment: a systematic review. Thyroid. 2010;20(10):1095–1101.
   PubMed Web of Science ®Google Scholar
• Bal, CS, Garg, A, Chopra, S, et al. Prognostic factors in pediatric differentiated thyroid cancer patients with pulmonary metastases. J Pediatr Endocrinol Metab. 2015;28(7–8):745–751.
   PubMed Web of Science ®Google Scholar
• Clement, SC, Kremer, LCM, Links, TP, et al. Is outcome of differentiated thyroid carcinoma influenced by tumor stage at diagnosis? Cancer Treat Rev. 2015;41(1):9–16.
   PubMed Web of Science ®Google Scholar
• Kim, A, Widemann, BC, Krailo, M, et al. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62(9):1562–1566.
   PubMed Web of Science ®Google Scholar
• Waguespack SG, Clayman, GL, Herzog, CE. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid. 2009;19(4):407–412.
   PubMed Web of Science ®Google Scholar
• Iyer P, Mayer 1033–1041, Ewig JM. Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. Thyroid. 2014;24(1):169–174.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Bowman HM, Tielsch JM, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–330.
   PubMed Web of Science ®Google Scholar
• Tuggle C, Roman S, Udelsman R, et al. Same-day thyroidectomy: a review of practice patterns and outcomes for 1168 procedures in New York State. Ann Surg Oncol. 2011;18:1035–1040.
   PubMed Web of Science ®Google Scholar
• Tuggle CT, Roman SA, Wang TS, et al. Pediatric endocrine surgery: who is operating on our children? Surgery. 2008;144:869–877.
   PubMed Web of Science ®Google Scholar
• Loyo M, Tufano RP, Gourin CG. National trends in thyroid surgery and the effect of volume on short-term outcomes. Laryngoscope. 2013;123:2056–2063.
   PubMed Web of Science ®Google Scholar
• Adam MA, Thomas S, Youngwirth L, et al. Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes? Ann Surg. 2017;265(2):402–407.
   PubMed Web of Science ®Google Scholar
• Breuer C, Tuggle C, Solomon D, et al.Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children? J Clin Res Pediatr Endocrinol.2013;1:79–85.
   Google Scholar
• Sosa, JA, Tuggle, CT, Wang, TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93(8):3058–3065.
   PubMed Web of Science ®Google Scholar
• Luster, M, Lassmann, M, Freudenberg, L, et al. Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. Hormones (Athens). 2007;6(4):269–278.
   PubMedGoogle Scholar
• Scholz, S, Smith, JR, Chaignaud, B, et al. Thyroid surgery at Children’s Hospital Boston: a 35-year single-institution experience. J Pediatr Surg. 2011;46(3):437–442.
   PubMed Web of Science ®Google Scholar
• Thompson GB, Hay ID. Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma. World J Surg. 2004;28(12):1187–1198.
   PubMed Web of Science ®Google Scholar
• Giordano, D, Valcavi, R, Thompson, GB, et al. Complications of central neck dissection in patients with papillary thyroid carcinoma: results of a study on 1087 patients and review of the literature. Thyroid. 2012;22(9):911–917.
   PubMed Web of Science ®Google Scholar
• Kim, MK, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg. 2004;130(10):1214–1216.
   PubMedGoogle Scholar
• Langer JE, Mandel SJ. Sonographic imaging of cervical lymph nodes in patients with thyroid cancer. Neuroimaging Clin N Am. 2008;18(3):479–489.
   PubMed Web of Science ®Google Scholar
• Popadich A, Levin O, Lee JC, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011;150:1048–1057.
   PubMed Web of Science ®Google Scholar
• Lang BH, Ng SH, Ll L, et al. A systematic review and meta-analysis of prophylactic central neck dissection on short-term loco-regional recurrence in papillary thyroid carcinoma after total thyroidectomy. Thyroid. 2013;23:1087–1098.
   PubMed Web of Science ®Google Scholar
• Wang TS, Cheung K, Farrokhyar F, et al. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20:3477–3483.
   PubMed Web of Science ®Google Scholar
• Palmer, BA, Zarroug, AE, Poley, RN, et al. Papillary thyroid carcinoma in children: risk factors and complications of disease recurrence. J Pediatr Surg. 2005;40(8):1284–1288.
   PubMed Web of Science ®Google Scholar
• Chen, Y, Masiakos, PT, Gaz, RD, et al. Pediatric thyroidectomy in a high volume thyroid surgery center: risk factors for postoperative hypocalcemia. J Pediatr Surg. 2015;50(8):1316–1319.
   PubMed Web of Science ®Google Scholar
• Chao, T-C, Jeng, L-B, Lin, J-D, et al. Reoperative thyroid surgery. World J Surg. 1997;21(6):644–647.
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyauchi A, Kobayashi K, et al. Static and dynamic prognostic factors of papillary thyroid carcinoma. Endocr J. 2014;61(12):1145–1151.
   PubMed Web of Science ®Google Scholar
• Rm T. Risk-adapted management of thyroid cancer. Endocr Pract. 2008;14:764–774.
   PubMedGoogle Scholar
• Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105–112.
   PubMed Web of Science ®Google Scholar
• Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–1349.
   PubMed Web of Science ®Google Scholar
• Vaisman F, Momesso D, Bulzico DA, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol. 2012;77: 132–138.
   PubMed Web of Science ®Google Scholar
• Castagna MG, Maino F, Cipri C, et al. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441–446.
   PubMed Web of Science ®Google Scholar